[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"regorafenib\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:regorafenib":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100619374","early-phase-1-efficacy-and-safety-study-of-dc-cik-cell-therapy-combined-with-epaloliposide-vortexil-and-regorafenib-as-third-line-treatment-for-advanced-colorectal-cancer-100619374",false,"NCT07343791","Efficacy and Safety Study of DC-CIK Cell Therapy Combined With Epaloliposide, Vortexil, and Regorafenib as Third-line Treatment for Advanced Colorectal Cancer.","Inclusion Criteria:\n\n-1. Sign written informed consent before implementing any experimental procedures; 2. Male or female ≥ 18 years old, ≤ 75 years old; 3. ECOG PS score is 0-1 points; 4. Patients with metastatic colorectal cancer confirmed by histology or cytology; 5. Expected survival time\\>3 months;\n\nExclusion Criteria:\n\n-1. It is known that there is active CNS metastasis and\u002For cancerous meningitis; 2. Chest fluid, ascites, and pericardial effusion that require drainage due to clinical symptoms; 3. Any life-threatening bleeding events that have occurred within the past 3 months, including the need for blood transfusion therapy, surgery or local treatment, and continuous medication therapy; 4. Uncontrollable hypertension, with systolic blood pressure\\>150mmHg or diastolic blood pressure\\>90 mmHg after optimal medical treatment, history of hypertensive crisis or hypertensive encephalopathy; 5. Human immunodeficiency virus (HIV) infected individuals (HIV 1\u002F2 antibody positive), known syphilis infected individuals;","ALL","18 Years","75 Years",{"count":19,"type":20},14,"ESTIMATED","INTERVENTIONAL",[23],"EARLY_PHASE1","Research background and purpose:\n\nPatients with advanced colorectal cancer face the dilemma of limited treatment options and poor efficacy in the third line treatment stage. Although regorafenib and immune checkpoint inhibitors bring hope to some patients, the efficacy still faces bottlenecks for the vast majority of microsatellite stable patients who are insensitive to immune monotherapy. This study is based on the multi mechanism synergistic theory of \"immune activation+vascular inhibition+targeted killing\". It innovatively combines autologous DC-CIK cell immunotherapy, domestic PD-1\u002FCTLA-4 bispecific antibody (aparolitovorelli monoclonal antibody), and multi-target tyrosine kinase inhibitor (regorafenib) to evaluate the efficacy and safety of this triple therapy as a third line treatment for advanced colorectal cancer, and explore its immunological mechanism.\n\nResearch content and methods:\n\nThis study is a single arm, open label clinical trial. Plan to enroll advanced colorectal cancer patients who have previously failed second-line standard treatment. All participants will receive the following combination therapy regimen:\n\n1. Epaglitovirizumab: 5.0 mg\u002Fkg, intravenous injection, once every 21 days.\n2. Regorafenib: 120mg, once daily, orally, 1-21 days, repeated every 28 days.\n3. DC-CIK cell therapy: Collect, culture, and transfuse cells during specific cycles.\n\nThe study will strictly follow the protocol for efficacy evaluation (based on RECIST 1.1 standards) and safety monitoring, and a strict quality control and risk management system will be established.\n\nMain evaluation indicators and expected outcomes:\n\n* Primary endpoint: Objective response rate and safety.\n* Secondary endpoints: progression free survival, overall survival, duration of remission, and treatment-related immunological responses.\n* Expected outcome: This study is expected to provide a promising new comprehensive treatment strategy for chemotherapy resistant advanced colorectal cancer, especially MSS type patients, and break through existing efficacy bottlenecks. The research findings will provide high-level evidence-based medicine for the clinical application of this combined approach and lay the foundation for understanding its synergistic mechanism.",[26,27,28,29,30],"DC-CIK Treatment","Regorafenib","Colorectal Cancer","Immune Combination Therapy","Iparomlimab and Tuvonralimab Injection",[32,27,33,34,30],"DC-CIK treatment","colorectal cancer","Immune combination therapy","RECRUITING","2026-01-14",{"date":38,"type":39},"2026-01-15","ACTUAL",{"date":41,"type":39},"2025-11-19",{"date":43,"type":20},"2027-11-30",{"name":45,"class":46},"JIANG LONGWEI","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":21,"phases":59,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":47},"100500339","phase-3-regorafenib-combined-with-irinotecan-drug-eluting-beads-for-colorectal-cancer-liver-metastases-100500339","NCT05794971","Regorafenib Combined With Irinotecan Drug-Eluting Beads for Colorectal Cancer Liver Metastases","Regorafenib Combined With Irinotecan Drug-Eluting Beads as Third-line Treatment for Colorectal Cancer Liver Metastases: a Multicentre, Randomised Phase 3 Trial (RIDER)","RIDER","Inclusion Criteria:\n\n* Patients over 18 years of age, of any race or sex, who have histologic or radiologic proof of colorectal cancer to the liver, who are able to give informed consent, will be eligible.\n* Patients failing first- and second-line standard systemic chemotherapy.\n* Patients with at least one measurable liver metastases, with size \\> 1cm response evaluation criteria in solid tumors (RECIST)\n* Patients with liver dominant disease defined as ≥80% tumor body burden confined to the liver\n* Less than 60% liver tumor replacement\n* Eastern Cooperative Oncology Group (ECOG) Performance Status score of \\\u003C 2\n* Child-pugh's grade A or B\n* Life expectancy of \\> 3 months\n* Non-pregnant with an acceptable contraception in premenopausal women.\n* Hematologic function: absolute neutrophil count (ANC) ≥ 1.5 x 109\u002FL, white cell count (WBC) ≥ 3.0 x 109\u002FL, platelets ≥75 x109\u002FL, international normalized ratio (INR) ≤1.3.\n* Adequate hepatic and renal function: Alanine aminotransferase (ALT) or aspartate aminotransferase ≤2.5×above upper normal range, total bilirubin≤1.5×above upper normal range, Serum creatinine≤1.5×above upper normal range\n* Women of child bearing potential and fertile men are required to use effective contraception negative serum beta human chorionic gonadotropin (βHCG)\n* Signed, written informed consent\n\nExclusion Criteria:\n\n* Prior treatment with TACE, regorafenib or fruquintinib\n* Patients with brain metastases\n* With serious heart, kidney, bone marrow, or lung, central nervous system diseases.\n* Patients suffered with other cancer.\n* patients who were seriously ill and had history of chronic disease such as tuberculosis (TB) and human immunodeficiency virus (HIV)\u002Facquired immune deficiency syndrome (AIDS) were excluded from the study.\n* known or suspected history of allergy to any of the related drugs used in the study\n* Women who are pregnant or breast feeding\n* Patients with serious somatic or psychiatric illness regarded as contraindications or in need of treatment that would interfere with study participation.","70 Years",{"count":58,"type":20},126,[60],"PHASE3","This study is a multicentre, prospective, randomised trial, aims to evaluate the efficacy and safety of Irinotecan Drug-Eluting Beads combined with regorafenib as the third-line treatment for a patient with colorectal cancer liver metastases. The study is planned to enrolled 126 patients failing first- and second-line standard chemotherapy treatment.",[63,27],"Colorectal Cancer Liver Metastases","2023-05-12",{"date":66,"type":39},"2023-05-15",{"date":68,"type":20},"2023-06-10",{"date":70,"type":20},"2028-03-31",{"name":72,"class":46},"Sun Yat-sen University"]